Alice P. Chen

18.8k citations

310 papers · 11.2k indexed · 2 hit papers · h-index 50

Impact in

Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research

Papers in

Oncology 145
- PARP inhibition in cancer therapy 69
- Cancer Treatment and Pharmacology 21
- Colorectal Cancer Treatments and Studies 19
Cancer Research 59
- Cancer Genomics and Diagnostics 45

Co-authors: James H. Doroshow Shivaani Kummar Robert J. Kinders Robert Persson Harry L.A. Janssen Michael R. Hodges M. Rodríguez‐Torres Yi Zhou
Journals: Journal of Clinical Oncology (84 papers)Clinical Cancer Research (15 papers)Cancer Chemotherapy and Pharmacology (14 papers)Cancer Research (13 papers)Molecular Cancer Therapeutics (11 papers)
Partner nations: United States Canada Taiwan

In The Last Decade

Alice P. Chen

289 papers receiving 11.0k citations

Hit Papers

align trajectories log scale

RECIST 1.1—Update and clarification: From the RECIST committee 2016 · 1.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 European Journal of Cancer
2013 New England Journal of Medicine

Peers

Countries citing papers authored by Alice P. Chen

Since Specialization

Citations

This map shows the geographic impact of Alice P. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice P. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice P. Chen more than expected).

Fields of papers citing papers by Alice P. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice P. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice P. Chen. The network helps show where Alice P. Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Alice P. Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alice P. Chen Line = papers co-authored together Alice P. Chen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Clinical Cancer Research ·Mohamed A. Gouda, Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng, Keyur P. Patel, Stanley R. Hamilton, Mark J. Routbort, James V. Tricoli, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F. Little, Carlos L. Arteaga, Peter J. O’Dwyer, Keith T. Flaherty, Lyndsay N. Harris, Funda Meric‐Bernstam	2025	1
2	Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H. Journal of Clinical Oncology ·April K.S. Salama, Victoria Wang, Erin Macrae, Jong‐In Park, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry Rubinstein, P. Mickey Williams, Stanley R. Hamilton, Deborah K. Armstrong, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty	2024	1
3	Molecular profiling of plasma from matched NCI-MATCH gynecological cancers. Journal of Clinical Oncology ·Amanda Peach, Bao T. Le, Vishnuprabha Rahul Kannan, Eric Greenbank, Rini Pauly, Li Chen, Ting-Chia Chang, Jennifer S. LoCoco, Lyndsay N. Harris, Alice P. Chen, Naoko Takebe, Traci Pawlowski, Lisa McShane, Peter J. O’Dwyer, James H. Doroshow, P. Mickey Williams, Biswajit Das, Chris Karlovich	2024	0
4	NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors Cancer Research Communications ·Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso	2023	2
5	Advances in the management of alveolar soft part sarcoma Current Problems in Cancer ·Geraldine O’Sullivan Coyne, Abdul Rafeh Naqash, Hari Sankaran, Alice P. Chen	2021	10
6	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute The Oncologist ·Arjun Mittra, Abdul Rafeh Naqash, James H. Murray, Shanda Finnigan, Joanne Kwak‐Kim, S. Percy Ivy, Alice P. Chen, Elad Sharon	2021	20
7	Nutrient composition and safety evaluation of simulated isobutanol distillers dried grains with solubles and associated fermentation metabolites when fed to male Ross 708 broiler chickens (Gallus domesticus) PLoS ONE ·Jason M. Roper, B. Smith, Jessica M. Caverly Rae, Emily Huang, Carl Walker, J.L. McNAUGHTON, Alice P. Chen, Kathy S. Reidinger	2019	2
8	Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers Clinical Cancer Research ·Deborah Wilsker, Allison Barrett, Angie B. Dull, Scott M. Lawrence, Melinda G. Hollingshead, Alice P. Chen, Shivaani Kummar, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders	2019	12
9	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia Clinical Cancer Research ·Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary L. Rosner, Alice P. Chen, Scott H. Kaufmann, Judith E. Karp	2016	38
10	Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors Journal of Clinical Oncology ·T. Khanh, Deborah Wilsker, Jiuping Ji, Jennifer Zlott, Tomoko Freshwater, Robert J. Kinders, Jerry M. Collins, Alice P. Chen, James H. Doroshow, Shivaani Kummar	2015	255
11	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis Clinical Cancer Research ·Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker‐Prietz, Robert J. Kinders, Lihua Wang, Alice P. Chen, Sarah M. Temkin, Naomi Horiba, Lillian L. Siu, Nilofer S. Azad	2014	58
12	National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network American Society of Clinical Oncology Educational Book ·Jeffrey S. Abrams, Barbara A. Conley, Margaret Mooney, James A. Zwiebel, Alice P. Chen, John J. Welch, Naoko Takebe, Shakun Malik, Lisa M. McShane, Edward L. Korn, Mickey Williams, Louis M. Staudt, James H. Doroshow	2014	122
13	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas Clinical Cancer Research ·Shivaani Kummar, Jiuping Ji, Robert J. Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian F. Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice P. Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow	2012	155
14	Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer Clinical Cancer Research ·Patricia A. Tang, Steven J. Cohen, Christian Kollmannsberger, Georg A. Bjarnason, Kiran Virik, Mary J. MacKenzie, Lillian Lourenço, Lisa Wang, Alice P. Chen, Malcolm J. Moore	2012	67
15	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report Clinical Cancer Research ·Julia Glade Bender, Susan M. Blaney, Scott C. Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte H. Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice P. Chen, Brenda J. Weigel, Peter C. Adamson, Julie R. Park	2012	16
16	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study Journal of Clinical Oncology ·John de Groot, Kathleen R. Lamborn, Susan M. Chang, Mark R. Gilbert, Timothy F. Cloughesy, Kenneth Aldape, Jun Yao, Edward F. Jackson, Frank S. Lieberman, H. Ian Robins, Minesh P. Mehta, Andrew B. Lassman, Lisa M. DeAngelis, W.K. Alfred Yung, Alice P. Chen, Michael D. Prados, Patrick Y. Wen	2011	168
17	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept Clinical Cancer Research ·John de Groot, Yuji Piao, Hai T. Tran, Mark R. Gilbert, Hua-Kang Wu, Jun Liu, B. Nebiyou Bekele, Tim Cloughesy, Minesh P. Mehta, H. Ian Robins, Andrew B. Lassman, Lisa M. DeAngelis, Kevin Camphausen, Alice P. Chen, W.K. Alfred Yung, Michael D. Prados, Patrick Y. Wen, John V. Heymach	2011	51
18	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors Clinical Cancer Research ·Igor Puzanov, Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen, Victoria J. Spanswick, Chih‐Yi Liao, John A. Hartley, Jordan Berlin, Mace L. Rothenberg	2011	35
19	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin Clinical Cancer Research ·Ahmad A. Tarhini, Paul Frankel, Kim Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice P. Chen, John M. Kirkwood	2011	62
20	An Improved Grafting Technique for Mature Arabidopsis Plants Demonstrates Long-Distance Shoot-to-Root Transport of Phytochelatins in Arabidopsis PLANT PHYSIOLOGY ·Alice P. Chen, Elizabeth A. Komives, Julian I. Schroeder	2006	123

About Alice P. Chen

Alice P. Chen is a scholar working on Oncology, Cancer Research, Genetics, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 310 papers that have together received 11.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (69 papers), Cancer Genomics and Diagnostics (45 papers), DNA Repair Mechanisms (39 papers), Lung Cancer Treatments and Mutations (24 papers), Cancer therapeutics and mechanisms (22 papers), Cancer Treatment and Pharmacology (21 papers), BRCA gene mutations in cancer (19 papers) and Colorectal Cancer Treatments and Studies (19 papers). The work is most often cited by research in Cancer Research (2.8k citations), Oncology (4.4k citations), Molecular Biology (4.7k citations), Pulmonary and Respiratory Medicine (2.0k citations) and Reproductive Medicine (484 citations). Alice P. Chen has collaborated with scholars based in United States, Canada and Taiwan. Frequent co-authors include James H. Doroshow, Shivaani Kummar, Robert J. Kinders, Robert Persson, Harry L.A. Janssen, Michael R. Hodges, M. Rodríguez‐Torres, Yi Zhou, Rozanne C. de Veer and Arthur A. Levin. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact